Notable Stock to Watch: Owens-Illinois (NYSE:OI)

Owens-Illinois (NYSE:OI).stock identified change of 8.23% away from 52-week low price and recently located move of -18.38% off 52-week high price. It has market worth of $2677.64M and dividend yield of 1.18%. OI stock has been recorded -4.57% away from 50 day moving average and -7.36% away from 200 day moving average. Moving closer, we can see that shares have been trading 0.73% off 20-day moving average.

 Owens-Illinois (NYSE:OI) has scheduled its second quarter 2019 conference call and webcast for Thursday, Aug. 1, 2019, at 8 a.m. EDT. The Company’s news release for the second quarter 2019 earnings will be issued after the market closes on Wednesday, Jul. 31.

At Owens-Illinois (NYSE: OI), we love glass and we’re proud to make more of it than any other glass bottle or jar producer in the world. We love that it’s beautiful, pure and completely recyclable. With global headquarters in Perrysburg, Ohio, we are the preferred partner for many of the world’s leading food and beverage brands. Working hand in hand with our customers, we give our passion and expertise to make their bottles iconic and help build their brands around the world. With more than 26,500 employees at 77 plants in 23 countries, O-I has global impact, achieving revenues of $6.9 billion in 2018.  The Consumer Goods sector company, Owens-Illinois noticed change of -1.68% to $16.96 along volume of 2079739 shares in recent session compared to an average volume of 1061.55K. The stock observed return of -0.47% in 5 days trading activity. The stock was at 0.47% over one month performance. OI’s shares are at -11.62% for the quarter and driving a -0.93% return over the course of the past year and is now at -1.62% since this point in 2018. 

 The average volatility for the week at 2.26% and for month was at 2.25%. There are 157.88M shares outstanding and 154.09M shares are floated in market. Right now the stock beta is 1.42. 

News Spotlight: Jensyn Acquisition Corp. (NASDAQ: JSYN)

Jensyn Acquisition Corp. (NASDAQ:JSYN) stock observed trading -58.12% off 52-week high price. On the other end, the stock has been noted 1.11% away from low price over the last 52-weeks. The stock disclosed a move of -52.90% away from 50 day moving average and -51.72% away from 200 day moving average. Moving closer, we can see that shares have been trading -51.79% off 20-day moving average. It has market cap of $9.14M.

 Jensyn Acquisition Corp. (NASDAQ:JSYN) a Special Purpose Acquisition Company (SPAC) and Peck Electric Co., a leading commercial solar engineering, procurement and construction (EPC) company,  announced that the business combination was overwhelmingly approved by Jensyn’s stockholders. The transaction is expected to close on June 20, 2019 subject to the satisfaction of customary closing conditions.

At the Special Meeting, more than 87% of the issued and outstanding shares which voted were in favor of the business combination.

Upon the closing of the business combination, the stockholders of Peck Electric Co. will exchange their shares in Peck Electric Co. for 3,234,501 shares of Jensyn common stock representing approximately 59% of Jensyn’s outstanding shares after giving effect to the business combination. In addition, the stockholders of Peck Electric Co. will be entitled to an additional 898,473 shares of Jensyn common stock if Jensyn’s adjusted EBITDA is $5,000,000 or more for the twelve-month period following the closing of the business combination or the closing price of Jensyn’s common stock is $12.00 or more at any time during such twelve-month period.

Consistent with the terms of the business combination, at the closing, Peck Electric Co. will become a wholly-owned subsidiary of Jensyn that will be named The Peck Company Holdings (Peck) whose common stock is expected to be listed on The NasdaqCapital Market under the symbol PECK.

Commenting on the vote from Peck Electric Co., Jeffrey Peck,Chief Executive Officer stated:  marks an exciting and important milestone for Peck Electric, as stockholders of Jensyn approved the business combination.  We believe this approval reflects their recognition and understanding of our history of profitable growth and that we are uniquely positioned to bring moreclean renewable energy online and capitalize on the significant growth opportunities across the Northeast and other key solar installation markets.  We look forward to executing on our growth strategy as a publicly traded company and delivering profitable growth to our stockholders.

Remarking from Jensyn, Jeffrey J. Raymond, President, CEO and Director, stated: We are very pleased to announce stockholders’ approval of our business combination with Peck Electric Co. – the leading solar EPC in the Northeast and one of the largest in the U.S.  Peck Electric has installed some of the largest commercial and utility-scale solar arrays in the state of Vermont and is poised to scale its profitable business through rapid expansion to other states throughout the Northeast.  We look forward to partnering with Peck Electric as a publicly traded company and helping them achieve their business objectives and deliver shareholder value.

The senior management of Peck will replace Jensyn’s existing management team following the closing of the business combination. Jeff Peck will serve as the Company’s CEO.  The USA based company Jensyn Acquisition Corp. moved with change of 0.00% to $5.03 with the total traded volume of 0 shares in recent session versus to an average volume of 12.15K. The stock was observed in the 5 days activity at -55.53%. The one month performance of stock was -52.73%. JSYN’s shares are at -51.78% for the quarter and driving a -50.64% return over the course of the past year and is now at -54.36% since this point in 2018.  . The average volatility for the week and month was at 23.18% and 6.06% respectively. There are 1.82M shares outstanding and 0.65M shares are floated in market.

Eye Catching Stock: Genocea Biosciences (NASDAQ:GNCA)

 Genocea Biosciences (NASDAQ:GNCA), changed -2.25% to recent value of $3.47. The stock transacted 392585 shares during most recent day however it has an average volume of 667.61K shares. It spotted trading -69.24% off 52-week high price. On the other end, the stock has been noted 54.91% away from the low price over the last 52-weeks.

 Genocea Biosciences (NASDAQ:GNCA), a biopharmaceutical company developing personalized cancer immunotherapies,  announced the pricing of its previously announced underwritten public offering of 10,500,000 shares of its common stock at a public offering price of $3.50 per share, before underwriting discounts and commissions. In addition, Genocea has granted the underwriters a 30-day option to purchase up to an additional 1,575,000 shares of common stock at the public offering price per share, less the underwriting discounts and commissions. The gross proceeds from the offering are expected to be $36,750,000 before deducting underwriting discounts and commissions and offering expenses payable by Genocea. All of the shares are being sold by Genocea. The offering is expected to close on or about June 24, 2019, subject to satisfaction of customary closing conditions.

SVB Leerink and Stifel are acting as joint book-running managers for the offering. Baird and Needham & Company are acting as co-managers for the offering. Its earnings per share (EPS) expected to touch remained 83.00% for this year

 The company has 14.38M of outstanding shares and 12.49M shares were floated in the market. According to the most recent quarter its current ratio was 2.5 that represents company’s ability to meet its current financial obligations. The price moved ahead of -32.51% from the mean of 20 days, -35.68% from mean of 50 days SMA and performed -31.48% from mean of 200 days price. Company’s performance for the week was -34.16%, -22.02% for month and YTD performance remained 51.24%.

Stock News in Focus: YY Inc. (NASDAQ:YY)

YY Inc. (NASDAQ:YY) stock identified change of 25.81% away from 52-week low price and recently located move of -39.63% off 52-week high price. It has market worth of $5729.58M. YY stock has been recorded -7.55% away from 50 day moving average and -2.33% away from 200 day moving average. Moving closer, we can see that shares have been trading -1.86% off 20-day moving average.

YY Inc. (NASDAQ:YY) a leading global social media platform, announced the pricing of its previously announced offering (the Notes Offering) of US$425 million in aggregate principal amount of convertible senior notes due 2025 (the 2025 Notes) and US$425 million in aggregate principal amount of convertible senior notes due 2026 (the 2026 Notes, and, together with the 2025 Notes, the Notes). The Company has granted the initial purchasers in the Notes Offering a 13-day option to purchase up to an additional US$75 million in aggregate principal amount of the 2025 Notes and US$75 million in aggregate principal amount of the 2026 Notes. The Company plans to use part of the net proceeds from the Notes Offering to pay the costs of the capped call transactions described below, and use the remainder of the proceeds for (i) global expansion-related initiatives, including infrastructure investment, personnel recruiting, sales and marketing and other efforts aimed at acquiring and servicing global users, (ii) video-based content offering expansion and enrichment, (iii) technology enhancement, and (iv) working capital and other general corporate purposes.

The Notes will bear interest at a rate of 0.75% per year, in the case of the 2025 Notes, and at a rate of 1.375% per year, in the case of the 2026 Notes. Interest on the Notes will accrue from, and including, June 24, 2019 and will be payable semiannually in arrears on June 15 and December 15 of each year, beginning on December 15, 2019. The Notes will be senior, unsecured obligations of YY. The 2025 Notes will mature on June 15, 2025 and the 2026 Notes will mature on June 15, 2026, unless repurchased, redeemed or converted in accordance with their terms prior to such date. The Company may not redeem the Notes prior to maturity, unless certain tax-related events occur. Holders of the Notes may require the Company to repurchase all or part of their Notes in cash on June 15, 2023, in the case of the 2025 Notes, and June 15, 2024, in the case of the 2026 Notes, or in the event of certain fundamental changes.  

The Technology sector company, YY Inc. noticed change of -1.60% to $69.89 along volume of 2036431 shares in recent session compared to an average volume of 1085.5K. The stock observed return of -5.23% in 5 days trading activity. The stock was at 4.00% over one month performance. YY’s shares are at -12.24% for the quarter and driving a -38.69% return over the course of the past year and is now at 16.76% since this point in 2018. 

 The average volatility for the week at 4.05% and for month was at 3.77%. There are 81.98M shares outstanding and 31.08M shares are floated in market. Right now the stock beta is 1.21. 

Notable News to Watch: Axovant Gene Therapies Ltd. (NASDAQ:AXGT)

Axovant Gene Therapies Ltd. (NASDAQ:AXGT) spotted trading -71.79% off 52-week high price. On the other end, the stock has been noted 80.05% away from the low price over the last 52-weeks. The stock changed 18.48% to recent value of $6.86. The stock transacted 19752742 shares during most recent day however it has an average volume of 282.8K shares. The company has 19.23M of outstanding shares and 9.51M shares were floated in the market.  

Axovant Gene Therapies Ltd. (NASDAQ:AXGT) a clinical-stage company developing innovative gene therapies,  announces it has signed a strategic partnership with Yposkesi, a leading Contract Development and Manufacturing Organization (CDMO) for preferred access and reserved capacity for cGMP grade viral vector production. Under this strategic collaboration, Yposkesi will provide expertise in process development, technology transfer, manufacturing scale-up, quality control and quality assurance. The ongoing prioritized access for manufacturing resources will support Axovant’s gene therapy programs as they proceed through development and commercialization, with an initial focus on the AAV-based gene therapies.

This partnership is expected to provide Axovant with sufficient manufacturing capacity to deliver our gene therapies to patients at scale, a key component for the continued development of our gene therapy pipeline, said Pavan Cheruvu, chief executive officer of Axovant. Partnering with Yposkesi’s global leaders and experts in cGMP-grade vector production strengthens our commitment to building a team with unmatched experience in gene therapy development. With reserved manufacturing capacity and dedicated suite space for Axovant and planned expansions in production capacity, Yposkesi is a preferred manufacturing partner. We look forward to working closely with its team.

Yposkesi is the largest European CDMO for gene therapy with capabilities to expand manufacturing for AAV and lentiviral vector production in its current 50,000 ft2 (approx. 5,000 m2) state-of-the-art facility, which houses multiple independent manufacturing suites. By 2021, Yposkesi plans to increase this footprint to 100,000 ft2 (approx. 10,000m2) to expand capacity with additional large-scale bioreactors (1,000 L) to further support growing demand for production. As a spin out from Genethon, a pioneer in the discovery and development of gene therapies, Yposkesi has 25 years of experience in GMP development and manufacturing and a team of over 150 scientific, industrial and technical specialists.  Yposkesi’s current manufacturing processes comply with both European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) manufacturing requirements.

We are excited to partner with Axovant to support the manufacture and delivery of its innovative gene therapies on a large-scale, said Alain Lamproye, chief executive officer of Yposkesi. Manufacturing is one of the most critical parts in the development of gene therapies, where expertise and available capacity are key factors.  Leaders in gene therapy, such as Axovant, are looking for state-of-the-art facilities, robust manufacturing capacity and years of expertise in producing cGMP-grade material. We strive to deliver industrial experience, innovation and support services to accelerate development of these innovative treatments.  Its earnings per share (EPS) expected to touch remained 51.40% for this year. 

 According to the most recent quarter its current ratio was 2.6 that represents company’s ability to meet its current financial obligations. The price moved ahead of 16.84% from the mean of 20 days, -7.99% from mean of 50 days SMA and performed -40.13% from mean of 200 days price. Company’s performance for the week was 33.98%, -8.53% for month and YTD performance remained -13.91%.

Notable News Spotlight: Colliers International Group Inc. (NASDAQ:CIGI)

Colliers International Group Inc. (NASDAQ:CIGI) spotted trading -16.28% off 52-week high price. On the other end, the stock has been noted 35.53% away from the low price over the last 52-weeks. The stock changed 0.30% to recent value of $70.49. The stock transacted 48354 shares during most recent day however it has an average volume of 78.86K shares. The company has 38.12M of outstanding shares and 36.27M shares were floated in the market.  

 Colliers International Group Inc. (NASDAQ:CIGI) announced  that Dylan Taylor has been terminated as Chief Executive Officer of its Real Estate Services division for misconduct including improper trading activity in Colliers securities in breach of his employment obligations. Mr. Taylor has made certain allegations which he asserts as the basis for a potential constructive dismissal claim. While management and the Board of Directors of Colliers have no reason to believe the validity of such claims, the Board has constituted a special committee to oversee an independent review of the allegations.

Jay Hennick, Chairman & Chief Executive Officer will continue to oversee the strategy and operations of Colliers as he has in the past, with all Regional and Business Line leaders directly reporting to him. John Friedrichsen, long-time Chief Financial Officer, will also take on added operational responsibilities. Effective immediately, the position of Chief Executive Officer of Real Estate Services is eliminated.  Its earnings per share (EPS) expected to touch remained 49.10% for this year while earning per share for the next 5-years is expected to reach at 20.00%. CIGI has a gross margin of 35.50% and an operating margin of 6.80% while its profit margin remained 3.20% for the last 12 months. 

 According to the most recent quarter its current ratio was 1 that represents company’s ability to meet its current financial obligations. The price moved ahead of 7.10% from the mean of 20 days, 8.06% from mean of 50 days SMA and performed 7.31% from mean of 200 days price. Company’s performance for the week was 2.91%, 14.14% for month and YTD performance remained 28.09%.

Notable Stock to Watch: BioSig Technologies (NASDAQ:BSGM)

BioSig Technologies (NASDAQ:BSGM) changed 3.93% to recent value of $9.25. The stock transacted 417302 shares during most recent day however it has an average volume of 185.35K shares. It spotted trading -7.22% off 52-week high price. On the other end, the stock has been noted 164.29% away from the low price over the last 52-weeks.

 BioSig Technologies (NASDAQ:BSGM) a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace,  announced that the Company has issued their June 2019 Shareholder Letter, highlighting successful patient cases using PURE EP™ System at three different medical centers, strengthening of patent portfolio and publication strategy, inclusion on the Russell 3000® Index, and other milestones moving toward commercialization.

Recent Company Highlights:

Successfully conducted patient cases using PURE EP™ System at Indiana University School of Medicine, Texas Cardiac Arrhythmia Institute and Greenville Memorial Hospital

Announced that the company is set to join the broad-market Russell 3000® Index at the conclusion of the 2019 Russell indexes annual reconstitution, effective after the US market opens on July 1, 2019

Announced that the U.S. Patent & Trademark Office allowed a U.S. patent application covering its PURE EP™ Simulator

Received a total of $4.6 million in warrant and option exercises in Q1 and Q2 2019

Announced that the U.S. Patent Office allowed 33 patent claims covering its PURE EP(tm) System.

Announced that Jerome Zeldis, M.D., Ph.D, former Chief Medical Officer of Celgene, re-joined BioSig as an Independent Director

BioSig’s manuscript entitled, Evaluation of Real Time Catheter Tissue Contact using Unipolar Intracardiac Signal Morphology was accepted at International Engineering in Medicine and Biology Conference 2019

Participated at the Heart Rhythm Society’s 40th Annual Scientific Sessions in San Francisco, CA

Appointed Frank J. Quintero and D.A. Wallach to Advisory Board

Completed private placement for $8,620,506 in March 2019

Appointed Dr. Barry Keenan, Ph.D, MBA, PMP to head up BioSig’s advanced product development.

The highlight of first five months of 2019 was, of course, the success of our first patient cases using PURE EP™ System at three different medical institutions, stated Mr. Kenneth Londoner, Founder, Chairman and CEO of BioSig Technologies. BioSig attended the Heart Rhythm Society’s 40th Annual Scientific Sessions and received outstanding feedback and support from the medical and scientific community. We have been working diligently towards commercialization and are excited that the PURE EP™ System has delivered great results during the first phase of external evaluation. Every area of our business has been solidified in the first five months of 2019 – strong balance sheet, exceptional human talent, first class clinical partners and robust intellectual property portfolio all mean that we’ve never been stronger as a Company. We would like to thank all our loyal shareholders – we never take your support for granted and will continue to work tirelessly on your behalf. Its earnings per share (EPS) expected to touch remained -17.30% for this year

 The company has 19.45M of outstanding shares and 13.67M shares were floated in the market. According to the most recent quarter its current ratio was 11 that represents company’s ability to meet its current financial obligations. The price moved ahead of 27.78% from the mean of 20 days, 28.27% from mean of 50 days SMA and performed 69.38% from mean of 200 days price. Company’s performance for the week was 16.94%, 31.95% for month and YTD performance remained 116.63%.

Is It Time To Review Stock News? Del Taco Restaurants (TACO)

 Del Taco Restaurants (TACO) spotted trading -18.21% off 52-week high price. On the other end, the stock has been noted 28.29% away from the low price over the last 52-weeks. The stock changed 1.85% to recent value of $12.13. The stock transacted 1099244 shares during most recent day however it has an average volume of 265.94K shares. The company has 36.22M of outstanding shares and 30.11M shares were floated in the market.  

Del Taco Restaurants (TACO) the nation’s second leading Mexican quick service restaurant, announced that after one of the most successful product launches in its history, the company is now expanding its partnership with Beyond Meat (NASDAQ: BYND) to offer the brand’s 100 percent plant-based protein option in two new signature protein-packed burritos, the Beyond 8 Layer Burrito and the Epic Beyond Cali Burrito, at its more than 580 locations across the country.

With the nationwide launch of its Beyond Tacos in April, Del Taco became the first national Mexican fast food chain to add a 100 percent plant-based protein option to its menu. Since then, Del Taco has sold nearly two million Beyond Tacos and Beyond Avocado Tacos, with close to 100,000 hand-sliced avocados used for the Beyond Avocado Taco alone.

The enthusiasm shown by our fans during the first weeks of our Beyond Meat offerings was undeniable, said John Cappasola, President and Chief Executive Officer of Del Taco. To that end, we wanted to reward the passion being shown across social media and in our restaurants by utilizing our uniquely seasoned Beyond Meat recipe in two new protein-packed burritos.

Healthcare as a whole is at a critical juncture: spending continues to skyrocket, burnout has been coined an official medical diagnosis, and organizations are failing to optimize the costly technology in which they have invested. The industry is begging for a solution to make healthcare work as it should, and with the role of the CFO evolving to have more of a strategic focus on data analytics, emphasis must be placed on education for organizations to make data more actionable in order to thrive financially and clinically. A recent Black Book research study reinforced the fact that analytics should play a critical role in the decision-making process at hospitals and health systems. The study highlighted cost control as the top concern for every healthcare leader including CFOs, who are leaning more into the technology and innovation realms than ever before.

The healthcare industry is experiencing a monumental shift on the analytics front, and CFOs and others in the financial departments of health systems are looking to better understand the nuts and bolts of Big Data in optimizing performance, driving ROI, and helping to reduce burnout, said Michael Clark, senior vice president and general manager, Nuance Communications. There is a demand for actionable insights in healthcare and real-time financial metrics to extract value for organizations and, as a company, we’re committed to advancing our analytical platform and self-service dashboard to help organizations and clinicians thrive now and in the future. Its earnings per share (EPS) expected to touch remained -7.10% for this year while earning per share for the next 5-years is expected to reach at 12.00%. TACO has a gross margin of 74.60% and an operating margin of 6.20% while its profit margin remained 3.40% for the last 12 months. 

 According to the most recent quarter its current ratio was 0.3 that represents company’s ability to meet its current financial obligations. The price moved ahead of 9.33% from the mean of 20 days, 11.58% from mean of 50 days SMA and performed 12.43% from mean of 200 days price. Company’s performance for the week was 7.35%, 5.02% for month and YTD performance remained 21.42%.

Stock News in Focus: Ocean Power Technologies (NASDAQ:OPTT)

Ocean Power Technologies (NASDAQ:OPTT) spotted trading -90.98% off 52-week high price. On the other end, the stock has been noted 14.82% away from the low price over the last 52-weeks. The stock changed -1.94% to recent value of $2.02. The stock transacted 245063 shares during most recent day however it has an average volume of 1177.74K shares. The company has 2.82M of outstanding shares and 2.78M shares were floated in the market.  

 Ocean Power Technologies (NASDAQ:OPTT) a leader in innovative and cost-effective ocean energy solutions, announced  that the Company has received a new U.S. patent for its Power Take-Off (PTO) System which is the mechanical heart of the PB3 PowerBuoy®. Ocean waves that pass-by the PowerBuoy® create a relative linear motion between the float and the spar components of the PB3. The PTO system takes the linear motion of the float through the input shaft and converts it into rotary motion via a ball-screw. The ball-screw drives a generator that produces electrical power thus completing the wave energy to electrical energy conversion.

George H. Kirby, President and Chief Executive Officer of OPT, stated, This new patent provides significant additional protection for our proprietary technology that enables the PowerBuoy® to be deployed and to perform autonomously in the toughest waters in the world. We continue to grow our extensive intellectual property patent portfolio, to capitalize on our prior investments in research & development, and to protect our breakthrough technology, which enables us to deliver the maximum value to our shareholders.

The PTO system has a mechanical efficiency of more than 90% and an expected minimum three years between service for continuous operation in the most severe environments, including the North Sea. The PTO system also contains a mechanical brake for locking the buoy during transportation and under storm conditions to prevent damage to the components.

This patent includes two different designs of the PTO system. The first design offsets the input rod and the ball-screw axes, which is currently being manufactured and deployed. The second design is based on a concentric input rod and ball-screw arrangement, which further simplifies the system and may be used in future PB3 PowerBuoy® deployments.

The newly issued patent increases the Company’s U.S. issued patent portfolio to 66 patents, of which 47 are active. The expiration dates for our issued U.S. patents run through 2037.

Outside of the U.S. we have been issued 237 patents across 13 countries with 37 of the active U.S. patents having at least one corresponding issued foreign patent. The Company’s patent portfolio includes patents and patent applications with claims directed to system design, control systems, power conversion, anchoring and mooring, and wave farm architecture. Its earnings per share (EPS) expected to touch remained 70.30% for this year. 

 According to the most recent quarter its current ratio was 1.3 that represents company’s ability to meet its current financial obligations. The price moved ahead of -1.44% from the mean of 20 days, -14.84% from mean of 50 days SMA and performed -70.98% from mean of 200 days price. Company’s performance for the week was 2.02%, -4.72% for month and YTD performance remained -70.30%.

Eye Catching Stock: Albireo Pharma (NASDAQ:ALBO)

Albireo Pharma (NASDAQ:ALBO) changed -1.79% to recent value of $31.22. The stock transacted 51874 shares during most recent day however it has an average volume of 55.38K shares. It spotted trading -19.31% off 52-week high price. On the other end, the stock has been noted 63.43% away from the low price over the last 52-weeks.

 Albireo Pharma (NASDAQ:ALBO) a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced  the launch of PFIC Voices, a new global campaign to build awareness and understanding of the burden of progressive familial intrahepatic cholestasis (PFIC), an ultra-rare, genetic, pediatric liver disease. Through PFIC Voices, Albireo is joining with leaders from the patient advocacy community, families and clinicians to share perspectives about the impact of PFIC, and the critical need for education, treatment and support.

Imagine the heartbreak of trying to console a child who is scratching herself so much day and night that she tears through her skin to the point of bleeding, said Emily Ventura, leader of PFIC Network (www.pfic.org), and mother to a PFIC patient. This is the experience of patients living with PFIC, and it affects the entire family. We are confronted with life-altering challenges in the present and an uncertain future. While we have made important progress in raising awareness in recent years, we must all join in the effort to support research that could lead to treatment. PFIC Voices is a way for patient and parent voices to be heard.

PFIC is rare but devastating, and those affected are desperate for relief—for their child and for the whole family. It is an inherited liver disease in which normal bile flow is disrupted, elevating bile acids to toxic levels. In many cases, patients diagnosed with PFIC progress to cirrhosis and experience end-stage liver disease by 10 years old. PFIC is estimated to affect one in every 50,000 to 100,000 children born worldwide. It is characterized by pruritus (intense itching), jaundice (yellowing of the skin), nutrient malabsorption, and poor weight gain and growth. PFIC is disruptive to sleep, leading to irritability and daytime fatigue for all family members. Itching may be so severe that it drives the decision to seek liver transplant. Liver transplant and other surgical interventions may fail, have complications, or bring psychological and social issues.

There are no approved treatments for PFIC, and healthcare providers have only limited options available to help manage this disease, said Dr. Patrick McKiernan, Director, Pediatric Hepatology Program, UPMC Children’s Hospital of Pittsburgh. These children usually need disfiguring surgeries or a liver transplant in addition to managing severe symptoms. Efforts to increase awareness of the impact of PFIC can play an important role in both improving treatment outcomes for patients, and driving research that could lead to new treatments in the years ahead. Its earnings per share (EPS) expected to touch remained -26.20% for this year

 The company has 12.26M of outstanding shares and 9.85M shares were floated in the market. According to the most recent quarter its current ratio was 15.5 that represents company’s ability to meet its current financial obligations. The price moved ahead of -4.52% from the mean of 20 days, -6.98% from mean of 50 days SMA and performed 6.76% from mean of 200 days price. Company’s performance for the week was -4.32%, -10.16% for month and YTD performance remained 27.27%.